# A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

> **NCT05731271** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Suzhou Transcenta Therapeutics Co., Ltd.** · enrollment: 111 (actual)

## Conditions studied

- Locally Advanced Solid Tumor
- Metastatic Tumor
- Colorectal Adenocarcinoma

## Interventions

- **DRUG:** TST003

## Key facts

- **NCT ID:** NCT05731271
- **Lead sponsor:** Suzhou Transcenta Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-08
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05731271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05731271, "A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05731271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*